Polygenic burden in focal and generalized epilepsies
- PMID: 31608925
- PMCID: PMC6821205
- DOI: 10.1093/brain/awz292
Polygenic burden in focal and generalized epilepsies
Erratum in
-
Corrigendum to: Polygenic burden in focal and generalized epilepsies.Brain. 2020 Jul 1;143(7):e61. doi: 10.1093/brain/awaa091. Brain. 2020. PMID: 32268364 Free PMC article. No abstract available.
Abstract
Rare genetic variants can cause epilepsy, and genetic testing has been widely adopted for severe, paediatric-onset epilepsies. The phenotypic consequences of common genetic risk burden for epilepsies and their potential future clinical applications have not yet been determined. Using polygenic risk scores (PRS) from a European-ancestry genome-wide association study in generalized and focal epilepsy, we quantified common genetic burden in patients with generalized epilepsy (GE-PRS) or focal epilepsy (FE-PRS) from two independent non-Finnish European cohorts (Epi25 Consortium, n = 5705; Cleveland Clinic Epilepsy Center, n = 620; both compared to 20 435 controls). One Finnish-ancestry population isolate (Finnish-ancestry Epi25, n = 449; compared to 1559 controls), two European-ancestry biobanks (UK Biobank, n = 383 656; Vanderbilt biorepository, n = 49 494), and one Japanese-ancestry biobank (BioBank Japan, n = 168 680) were used for additional replications. Across 8386 patients with epilepsy and 622 212 population controls, we found and replicated significantly higher GE-PRS in patients with generalized epilepsy of European-ancestry compared to patients with focal epilepsy (Epi25: P = 1.64×10-15; Cleveland: P = 2.85×10-4; Finnish-ancestry Epi25: P = 1.80×10-4) or population controls (Epi25: P = 2.35×10-70; Cleveland: P = 1.43×10-7; Finnish-ancestry Epi25: P = 3.11×10-4; UK Biobank and Vanderbilt biorepository meta-analysis: P = 7.99×10-4). FE-PRS were significantly higher in patients with focal epilepsy compared to controls in the non-Finnish, non-biobank cohorts (Epi25: P = 5.74×10-19; Cleveland: P = 1.69×10-6). European ancestry-derived PRS did not predict generalized epilepsy or focal epilepsy in Japanese-ancestry individuals. Finally, we observed a significant 4.6-fold and a 4.5-fold enrichment of patients with generalized epilepsy compared to controls in the top 0.5% highest GE-PRS of the two non-Finnish European cohorts (Epi25: P = 2.60×10-15; Cleveland: P = 1.39×10-2). We conclude that common variant risk associated with epilepsy is significantly enriched in multiple cohorts of patients with epilepsy compared to controls-in particular for generalized epilepsy. As sample sizes and PRS accuracy continue to increase with further common variant discovery, PRS could complement established clinical biomarkers and augment genetic testing for patient classification, comorbidity research, and potentially targeted treatment.
Keywords: common variant risk; epilepsy; genetic generalized epilepsy; genetics.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.
Figures


Comment in
-
The first step towards personalized risk prediction for common epilepsies.Brain. 2019 Nov 1;142(11):3316-3318. doi: 10.1093/brain/awz318. Brain. 2019. PMID: 31665751 No abstract available.
Similar articles
-
Phenotypic heterogeneity in familial epilepsies is influenced by polygenic risk for generalized and focal epilepsies.Epilepsia. 2025 Jun;66(6):2036-2045. doi: 10.1111/epi.18348. Epub 2025 Mar 6. Epilepsia. 2025. PMID: 40047626 Free PMC article.
-
Common risk variants for epilepsy are enriched in families previously targeted for rare monogenic variant discovery.EBioMedicine. 2022 Jul;81:104079. doi: 10.1016/j.ebiom.2022.104079. Epub 2022 May 27. EBioMedicine. 2022. PMID: 35636315 Free PMC article.
-
Pleiotropy of polygenic factors associated with focal and generalized epilepsy in the general population.PLoS One. 2020 Apr 28;15(4):e0232292. doi: 10.1371/journal.pone.0232292. eCollection 2020. PLoS One. 2020. PMID: 32343744 Free PMC article.
-
Predictive value of the polygenic risk score for developing epilepsy: a systematic review and meta-analysis.Epilepsy Behav. 2025 Aug;169:110438. doi: 10.1016/j.yebeh.2025.110438. Epub 2025 May 3. Epilepsy Behav. 2025. PMID: 40319673 Review.
-
Genome-Wide Insights and Polygenic Risk Scores in Common Epilepsies: A Narrative Review.Am J Med Genet B Neuropsychiatr Genet. 2025 Jun 13:e33040. doi: 10.1002/ajmg.b.33040. Online ahead of print. Am J Med Genet B Neuropsychiatr Genet. 2025. PMID: 40511554 Review.
Cited by
-
Genetic Testing in Epilepsy: Improving Outcomes and Informing Gaps in Research.Epilepsy Curr. 2024 Mar 25;25(3):153-157. doi: 10.1177/15357597241232881. eCollection 2025 May-Jun. Epilepsy Curr. 2024. PMID: 39554273 Free PMC article. Review.
-
SLC6A1 variant pathogenicity, molecular function and phenotype: a genetic and clinical analysis.Brain. 2023 Dec 1;146(12):5198-5208. doi: 10.1093/brain/awad292. Brain. 2023. PMID: 37647852 Free PMC article.
-
The impact of low-risk genetic variants in self-limited epilepsy with centrotemporal spikes aka Rolandic epilepsy.EBioMedicine. 2020 Aug;58:102896. doi: 10.1016/j.ebiom.2020.102896. Epub 2020 Jul 21. EBioMedicine. 2020. PMID: 32702638 Free PMC article. No abstract available.
-
Polygenic risk scores in epilepsy.Med Genet. 2022 Sep 22;34(3):225-230. doi: 10.1515/medgen-2022-2146. eCollection 2022 Oct. Med Genet. 2022. PMID: 38835881 Free PMC article.
-
Assessing the role of rare genetic variants in drug-resistant, non-lesional focal epilepsy.Ann Clin Transl Neurol. 2021 Jul;8(7):1376-1387. doi: 10.1002/acn3.51374. Epub 2021 May 21. Ann Clin Transl Neurol. 2021. PMID: 34018700 Free PMC article.
References
-
- Bell GS, Neligan A, Giavasi C, Keezer MR, Novy J, Peacock JL, et al. Outcome of seizures in the general population after 25 years: a prospective follow-up, observational cohort study. J Neurol Neurosurg Psychiatry 2016; 87: 843–50. - PubMed
-
- Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology 1991; 41: 965–72. - PubMed
-
- Borodulin K, Tolonen H, Jousilahti P, Jula A, Juolevi A, Koskinen S, et al. Cohort profile: the National FINRISK study. Int J Epidemiol 2017. - PubMed